Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8599)	2/3/1999 1:47:00 PM
From: Cacaito	Read Replies (3) \| Respond to of 17367

Three arms then it is not 175 on each group, 350/3 = 116 each arm. There will not be 15% mortality in the placebo group, forget that. If there is then Xoma should patent the placebo and forget about Bpi. Mortality in septic shock is 20% to 60%. Check the Barcelona area, Spanish study you provided the abstract and I gave the full article numbers like a month ago. Expect something like Placebo 35% to 24% vs treatment 15% to 12%. About 150 patients on each group are necessary. Recruitment must continue. The many times mentioned low deaths in the placebo group is not based in reality. Nothing has changed from the phase II time. More than 3000 patients included in the meta-analysis from Critical Care Medicine Journal: 35% mortality across the board in about 18 phase III studies. This patients received the best care available. (USA and Western Europe).